Versant Capital Management’s AbbVie ABBV Stock Holding History

Versant Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.74M	Sell	6,899 -1,170	-14%	-$252K	0.16%	82
2026 Q1	$1.75M	Buy	8,069 +2,081	+35%	+$462K	0.17%	72
2025 Q4	$1.37M	Sell	5,988 -1,438	-19%	-$328K	0.17%	72
2025 Q3	$1.72M	Buy	7,426 +1,994	+37%	+$406K	0.23%	65
2025 Q2	$1.01M	Buy	5,432 +281	+5%	+$52.2K	0.15%	77
2025 Q1	$1.08M	Buy	5,151 +2,416	+88%	+$470K	0.18%	69
2024 Q4	$486K	Buy	2,735 +693	+34%	+$127K	0.1%	97
2024 Q3	$403K	Buy	2,042 +616	+43%	+$115K	0.09%	95
2024 Q2	$245K	Sell	1,426 -104	-7%	-$17.2K	0.06%	124
2024 Q1	$279K	Sell	1,530 -696	-31%	-$120K	0.08%	103
2023 Q4	$345K	Sell	2,226 -17	-0.8%	-$2.48K	0.1%	86
2023 Q3	$334K	Buy	2,243 +33	+1%	+$4.84K	0.11%	86
2023 Q2	$298K	Sell	2,210 -9	-0.4%	-$1.32K	0.1%	96
2023 Q1	$354K	Buy	2,219 +57	+3%	+$8.71K	0.12%	83
2022 Q4	$349K	Buy	2,162 +10	+0.5%	+$1.53K	0.13%	78
2022 Q3	$289K	Buy	2,152 +47	+2%	+$6.74K	0.11%	81
2022 Q2	$322K	Buy	2,105 +4	+0.2%	+$611	0.12%	81
2022 Q1	$341K	Buy	2,101 +6	+0.3%	+$872	0.11%	84
2021 Q4	$284K	Buy	2,095 +118	+6%	+$13.9K	0.09%	89
2021 Q3	$213K	Buy	1,977 +230	+13%	+$26.3K	0.08%	93
2021 Q2	$197K	Buy	1,747 +27	+2%	+$3.04K	0.07%	94
2021 Q1	$186K	Buy	1,720 +517	+43%	+$55.3K	0.07%	106
2020 Q4	$128K	Sell	1,203 -1,913	-61%	-$184K	0.05%	127
2020 Q3	$272K	Buy	3,116 +11	+0.4%	+$1.04K	0.12%	81
2020 Q2	$304K	Buy	3,105 +41	+1%	+$3.61K	0.14%	71
2020 Q1	$233K	Buy	3,064 +144	+5%	+$12.3K	0.12%	75
2019 Q4	$258K	Sell	2,920 -36	-1%	-$2.99K	0.13%	68
2019 Q3	$223K	Sell	2,956 -184	-6%	-$12.6K	0.1%	77
2019 Q2	$228K	Sell	3,140 -319	-9%	-$25.1K	0.1%	82
2019 Q1	$278K	Sell	3,459 -373	-10%	-$30.5K	0.12%	74
2018 Q4	$353K	Hold	3,832	–	–	0.16%	64
2018 Q3	$362K	Sell	3,832 -82	-2%	-$7.78K	0.15%	64
2018 Q2	$362K	Sell	3,914 -18	-0.5%	-$1.76K	0.15%	69
2018 Q1	$372K	Sell	3,932 -146	-4%	-$16K	0.15%	69
2017 Q4	$394K	Buy	4,078 +304	+8%	+$28.7K	0.16%	73
2017 Q3	$335K	Hold	3,774	–	–	0.18%	55
2017 Q2	$273K	Buy	3,774 +10	+0.3%	+$672	0.15%	60
2017 Q1	$245K	Hold	3,764	–	–	0.14%	64
2016 Q4	$235K	Sell	3,764 -14	-0.4%	-$855	0.13%	64
2016 Q3	$238K	Sell	3,778 -28	-0.7%	-$1.81K	0.14%	69
2016 Q2	$235K	Sell	3,806 -37	-1%	-$2.25K	0.14%	64
2016 Q1	$219K	Sell	3,843 -26	-0.7%	-$1.45K	0.13%	65
2015 Q4	$229K	Buy	+3,869	New	+$223K	0.14%	61

Other funds holding ABBV

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

HCM

Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

HPC

HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return

Versant Capital Management's ABBV Position: Q2 2026 in Review

Versant Capital Management reduced its AbbVie (ABBV) stake by 14% in Q2 2026, selling an estimated $252K and leaving 6,899 shares worth $1.74M. The position accounts for 0.16% of the portfolio, ranked #82.

Versant Capital Management first reported a position in ABBV in Q4 2015 and has held it in 43 quarters since. The position peaked at $1.75M in Q1 2026. 1,191 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Versant Capital Management held 6,899 shares of AbbVie worth $1.74M as of Q2 2026.
Versant Capital Management sold 1,170 AbbVie shares in Q2 2026, an estimated $252K.
AbbVie made up 0.16% of Versant Capital Management's portfolio in Q2 2026, its #82 holding.
Versant Capital Management first reported a position in AbbVie in Q4 2015 and has held it in 43 quarters since.
Versant Capital Management's AbbVie position peaked at $1.75M in Q1 2026.
1,191 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.